Home > Healthcare > Hairy Cell Leukemia Market

Hairy Cell Leukemia Market Trends

Report ID: GMI8334
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Hairy Cell Leukemia Market Trends

Rising incidence rates of hematological malignancies, bolstered by improved diagnostic capabilities, results in a higher frequency of HCL diagnoses. This trend is anticipated to fuel demand for HCL treatments and drive market landscape.
Further, rising geriatric population is a key growth driver. HCL can affect individuals at any age, but the majority of patients are diagnosed between the ages of 50 and 60 years. For instance, according to European Commission, more than one fifth i.e., about 21.1% of European population with HCL was aged over 65 in 2022.
Moreover, continuous advancements in treatment options for HCL, including novel targeted therapies and immunotherapies, contribute significantly to market growth. These innovative treatments offer improved efficacy, reduced side effects, and better outcomes for patients.

However, limited awareness pertaining to the disease and high cost associated with treatment can hamper the growth of the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Hairy cell leukemia market size was USD 130.7 million in 2023 and is expected to register 6.5% CAGR from 2024-2032 owing to the increasing incidence rates of blood related cancers, advancements in diagnosis and rare disease treatment options, and emerging oncology therapies worldwide.

The chemotherapy segment held 65.2% share in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to being a standard treatment offer and acting as a first-line therapy for newly diagnosed HCL patients.

Asia Pacific hairy cell leukemia industry garnered 43.6% share in 2023 and is expected to register a commendable CAGR from 2024-2032 due to the presence of a large population and high incidence of leukemia cases in the region.

Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., and Takeda Pharmaceutical Company Limited, are some of the major hairy cell leukemia companies worldwide.